SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies addressing complications of renal disease, announced today the discovery of a clinical candidate for chronic treatment of complications of cardiorenal disease. Earlier this year, Tricida closed a $10 million Series A financing led by OrbiMed Advisors, with investments by Sibling Capital Ventures and Limulus Venture Partners. Sibling Capital Ventures, Tricida’s founding investor, provided seed funding to enable pre-clinical activities and market validation studies ahead of the Series A financing.
Hey, check out all the research scientist jobs. Post your resume today!
